Epstein-Barr Virus is Associated With Aggressive Subtypes of Invasive Ductal Carcinoma of Breast (Her2+/ER- and Triple Negative) and With Nuclear Expression of NF?B p50

Main Article Content

Ashley James Ballard


Epstein-Barr virus, Breast cancer, Estrogen receptor, Her2 receptor, Nuclear factor κB


Background: A growing body of evidence suggests a possible role for Epstein-Barr virus (EBV) in the pathogenesis of a subset of breast cancers, with many of these studies highlighting an increased association between EBV and aggressive forms of breast carcinoma. This study aimed to further investigate this issue by assessing the possible association between EBV and the Her2+/ER- and Triple negative sub types of invasive ductal carcinoma (IDC).
Methods: An immunohistochemical marker for EBV (Epstein-Barr virus nuclear antigen 1 (EBNA1) clone E1-2.5) was applied to tissue micro array sections. The tissue micro array's contained 58 cases of Her2+/ER- IDC, 57 cases of triple negative IDC and 67 cases of luminal like IDC. Each case was scored as positive or negative for nuclear expression of EBNA1 in tumour cells using standard light microscopy. Clinical and pathological details where noted for each case, as was the nuclear expression of NF?B p50.
Results: EBV infection was apparent in 43.2% of all cases. By subtype EBV was evident in 31 (57.4%) Her2+/ER- cases, 28 (49.1%) triple negative cases, and 14 (24.1%) luminal like cases; with a significant association being noted between the Her2+/ER- and triple negative cases and EBV infection (P 0.001). This association was primarily linked with ER negativity, Her2 status showed no significant association with EBV infection. There were no significant associations with other clinical and pathological characteristics. Of the 53 cases demonstrating NF?B p50 nuclear staining, 37 (69.8%) were also infected by EBV (P <0.001).
Conclusion: This study provides evidence that EBV is associated with aggressive subtypes of IDC (Her2+/ER- and triple negative) as well as providing evidence for a link between EBV and NF?B p50 nuclear expression, although the nature of these associations remains unclear.


1. Burgos JS. Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis. Medical oncology. 2005;22(2):113-21.
2. Fukayama M, Ushiku T. Epstein-Barr virus-associated gastric carcinoma. Pathology, research and practice. 2011;207(9):529-37.
3. Mazouni C, Fina F, Romain S, Ouafik L, Bonnier P, Brandone JM, et al. Epstein-Barr virus as a marker of biological aggressiveness in breast cancer. British journal of cancer. 2011;104(2):332-7.
4. Hachana M, Amara K, Ziadi S, Romdhane E, Gacem RB, Trimeche M. Investigation of Epstein-Barr virus in breast carcinomas in Tunisia. Pathology, research and practice. 2011;207(11):695-700.
5. Murray PG, Lissauer D, Junying J, Davies G, Moore S, Bell A, et al. Reactivity with A monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1 defines a subset of aggressive breast cancers in the absence of the EBV genome. Cancer research. 2003;63(9):2338-43.
6. Glenn WK, Heng B, Delprado W, Iacopetta B, Whitaker NJ, Lawson JS. Epstein-Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer. PloS one. 2012;7(11):e48788.
7. Fawzy S, Sallam M, Awad NM. Detection of Epstein-Barr virus in breast carcinoma in Egyptian women. Clinical biochemistry. 2008;41(7-8):486-92.
8. Joshi D, Quadri M, Gangane N, Joshi R, Gangane N. Association of Epstein Barr virus infection (EBV) with breast cancer in rural Indian women. PloS one. 2009;4(12):e8180.
9. Fina F, Romain S, Ouafik L, Palmari J, Ben Ayed F, Benharkat S, et al. Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas. British journal of cancer. 2001;84(6):783-90.
10. Preciado MV, Chabay PA, De Matteo EN, Gonzalez P, Grinstein S, Actis A, et al. Epstein-Barr virus in breast carcinoma in Argentina. Archives of pathology & laboratory medicine. 2005;129(3):377-81.
11. Zekri AR, Bahnassy AA, Mohamed WS, El-Kassem FA, El-Khalidi SJ, Hafez MM, et al. Epstein-Barr virus and breast cancer: epidemiological and molecular study on Egyptian and Iraqi women. Journal of the Egyptian National Cancer Institute. 2012;24(3):123-31.
12. Labrecque LG, Barnes DM, Fentiman IS, Griffin BE. Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer research. 1995;55(1):39-45.
13. Luqmani Y, Shousha S. Presence of epstein-barr-virus in breast-carcinoma. International journal of oncology. 1995;6(4):899-903.
14. Huo Q, Zhang N, Yang Q. Epstein-Barr virus infection and sporadic breast cancer risk: a meta-analysis. PloS one. 2012;7(2):e31656.
15. Lin JH, Tsai CH, Chu JS, Chen JY, Takada K, Shew JY. Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells. Journal of virology. 2007;81(11):5705-13.
16. Tang W, Morgan DR, Meyers MO, Dominguez RL, Martinez E, Kakudo K, et al. Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile. Infectious agents and cancer. 2012;7(1):21.
17. Fukayama M, Hino R, Uozaki H. Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer science. 2008;99(9):1726-33.
18. Ren Q, Sato H, Murono S, Furukawa M, Yoshizaki T. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line. The Laryngoscope. 2004;114(5):855-9.
19. Lorenzetti MA, De Matteo E, Gass H, Martinez Vazquez P, Lara J, Gonzalez P, et al. Characterization of Epstein Barr virus latency pattern in Argentine breast carcinoma. PloS one. 2010;5(10):e13603.
20. Murray PG. Epstein-Barr virus in breast cancer: artefact or aetiological agent? The Journal of pathology. 2006;209(4):427-9.
21. Xue SA, Lampert IA, Haldane JS, Bridger JE, Griffin BE. Epstein-Barr virus gene expression in human breast cancer: protagonist or passenger? British journal of cancer. 2003;89(1):113-9.
22. Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009;18(4):1157-66.
23. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008;52(1):108-18.
24. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007;13(8):2329-34.
25. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer investigation. 2008;26(1):1-10.
26. Khan G, Philip PS, Al Ashari M, Houcinat Y, Daoud S. Localization of Epstein-Barr virus to infiltrating lymphocytes in breast carcinomas and not malignant cells. Experimental and molecular pathology. 2011;91(1):466-70.
27. Thornburg NJ, Raab-Traub N. Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal-activating region 1 is mediated by NF-kappaB p50 homodimer/Bcl-3 complexes. Journal of virology. 2007;81(23):12954-61.
28. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202-9.
29. Barton S, Zabaglo L, A'Hern R, Turner N, Ferguson T, O'Neill S, et al. Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. British journal of cancer. 2012;106(11):1760-5.
30. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(32):4273-8.
31. Ahmed KM, Cao N, Li JJ. HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. Anticancer research. 2006;26(6B):4235-43.
32. Shapochka DO, Zaletok SP, Gnidyuk MI. Relationship between NF-kappaB, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer. Experimental oncology. 2012;34(4):358-63.
33. Biswas DK, Iglehart JD. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. Journal of cellular physiology. 2006;209(3):645-52.
34. Yde CW, Emdal KB, Guerra B, Lykkesfeldt AE. NFkappaB signaling is important for growth of antiestrogen resistant breast cancer cells. Breast cancer research and treatment. 2012;135(1):67-78.
35. Kung CP, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3. Journal of virology. 2008;82(11):5486-93.
36. Kung CP, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 modulates distinctive NF- kappaB pathways through C-terminus-activating region 1 to regulate epidermal growth factor receptor expression. Journal of virology. 2010;84(13):6605-14.
37. Hino R, Uozaki H, Inoue Y, Shintani Y, Ushiku T, Sakatani T, et al. Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A. Cancer research. 2008;68(5):1427-35.

Article Statistics :Views : 1378 | Downloads : 776